A national, phase II clinical trial examining the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease has begun as more than two dozen academic institutions recruit volunteers in the coming months. R. Scott Turner, M.D., Ph.D., director of Georgetown University Medical Center's Memory Disorders Program, is the lead investigator for the national study.
Resveratrol is a compound found in red grapes, red grape juice, red wine, chocolate, tomatoes and peanuts. Pre-clinical and pilot clinical research studies suggest that resveratrol may prevent diabetes, act as a natural cancer fighter, ward off cardiovascular disease, and prevent memory loss, but there has been no large definitive study of its effects in humans.
The risk of all of these diseases increases with aging. Animal studies suggest that resveratrol may impede molecular mechanisms of aging. Human population studies suggest several health benefits from modest daily consumption of red wine, but the mechanisms of action in the body are unknown.
"Most resveratrol studies showing any health benefits have been conducted in animal models, such as mice, and with doses that far exceed intake from sipping wine or nibbling on chocolate," says Turner. "With this clinical trial, we'll find out if daily doses of pure resveratrol can delay or alter memory deterioration and daily functioning in people with mild to moderate dementia due to Alzheimer's."
"During this study, we will also test whether resveratrol improves glucose and insulin metabolism in older individuals -- although those who already have diabetes will not be included in this study."
Resveratrol is not approved by the Food and Drug Administration for the treatment of Alzheimer's. It is not known if resveratrol can change the course of the disease.
Not everyone who enrolls in the study will receive resveratrol. Half of the participants will receive a placebo (a sugar pill made to look like the resveratrol pill) to allow researchers to more objectively test the benefits of resveratrol. Neither the patient nor the clinical staff will know if the study participant is receiving the placebo or resveratrol until the end of the study.
"This is the gold-standard for conducting a clinical study because it allows us to objectively determine if resveratrol is offering any benefits," explains Brigid Reynolds, NP, lead investigator for the study at Georgetown.
In addition, the phase II study will examine the safety and tolerability of resveratrol administered twice daily with a dose increase planned at three-month intervals, she says.
According to the National Institute of Aging, more than 5.3 million people in the U.S. are suffering from Alzheimer's, and every 70 seconds, another person develops this disease. In Washington, DC, more than 9,000 people aged 65 and older are currently living with Alzheimer's.
The resveratrol study will be conducted at 26 U.S. academic institutions that are affiliated with the Alzheimer's Disease Cooperative Study. Patients who volunteer for the study cannot be enrolled in another clinical trial during the study period. They will also be asked to abstain from eating or drinking large quantities of foods or beverages that contain resveratrol, and abstain from taking dietary supplements containing resveratrol.
Each patient will be in the study for a twelve-month period and will require a study partner (spouse, friend or caregiver) to visit the Georgetown University Medical Center 10 times over the course of that year. Participants must be willing and able to undergo two lumbar punctures (a procedure where a needle is inserted into the lower spine to collect fluid), three MRI scans of the brain, and blood and urine tests during the course of the study.
The research is sponsored by the Alzheimer's Disease Cooperative Study (ADCS), through a grant from the National Institute on Aging (NIA). Turner and Reynolds report no personal financial interests related to the study.
To learn more about the resveratrol study or other Alzheimer's studies underway at Georgetown, contact Kelly Behan in the GUMC Memory Disorders Program by calling (202) 687-0413 or by emailing her at email@example.com. Information is also available at memory.georgetown.edu. Georgetown study participants must speak English.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university's sponsored research funding.
Karen Mallet | EurekAlert!
Antarctic Ice Sheet mass loss has increased
14.06.2018 | Technische Universität Dresden
WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
21.06.2018 | Earth Sciences
21.06.2018 | Life Sciences
21.06.2018 | Earth Sciences